Publications by authors named "B J Kullberg"
Background: Rezafungin is an echinocandin approved in the US and EU to treat candidaemia and/or invasive candidiasis. This post-hoc, pooled analysis of the Phase 2 STRIVE and Phase 3 ReSTORE trials assessed rezafungin versus caspofungin in patients with candidaemia and/or invasive candidiasis (IC) in the intensive care unit (ICU) at randomisation.
Methods: STRIVE and ReSTORE were randomised double-blind trials in adults with systemic signs and mycological confirmation of candidaemia and/or IC in blood or a normally sterile site ≤ 96 h before randomisation.
Article Synopsis
- Rezafungin, a new once-weekly echinocandin, showed similar effectiveness to caspofungin in treating candidemia and invasive candidiasis in the ReSTORE trial, particularly in terms of day 30 all-cause mortality and day 14 global cure rates.
- The study involved patients aged 18 and older, comparing the outcomes of those receiving rezafungin to those on caspofungin, with specific focus on patients who had a positive culture close to the time of treatment randomization.
- Results indicated comparable safety and efficacy between the two treatments, with rezafungin showing potential advantages in early mycological response, suggesting it could be an effective option for treatment.
Article Synopsis
- * Researchers analyzed cytokine production before and after antibiotic treatment in over 1,000 patients, discovering a negative relationship between antibody production and IL-10 levels, as well as increased IL-1Ra in those with advanced disease.
- * Genome-wide mapping identified 34 cytokine quantitative trait loci (cQTLs), including 31 new ones, linking immune responses to Lyme borreliosis susceptibility and offering insights relevant to other immune-related diseases.
Article Synopsis
- Genetic variation affects how individuals respond to infections, influencing both susceptibility and symptoms of diseases like Lyme borreliosis (LB).
- The study involved genome-wide association studies of 1,138 LB patients and healthy controls, evaluating genetic variants, cytokine responses, and antibody production related to the disease.
- A newly identified genetic variant, rs1061632, was linked to increased susceptibility to LB and associated with immune response alterations, highlighting the genetic factors influencing LB susceptibility and bacterial clearance.
Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM.
Matteo Bassetti Daniele R Giacobbe Christina Agvald-Ohman Murat Akova Ana Alastruey-Izquierdo Bart J Kullberg
Intensive Care Med
April 2024
Article Synopsis
- The document outlines the goal of creating standardized research definitions for invasive fungal diseases (IFD) in adult ICU patients without typical risk factors for these infections.
- A panel of experts assessed existing definitions and lab tests for IFD, using the RAND/UCLA method to reach a consensus on new definitions.
- Key standardized definitions were made for conditions like invasive candidiasis and aspergillosis, but more data is needed for other IFDs, with the intent to enhance future research studies.